Takeda teams with GammaDelta to develop novel cell therapies

By Gareth Macdonald

- Last updated on GMT

(Source Takeda)
(Source Takeda)

Related tags Protein Cancer

Takeda has teamed up with GammaDelta Therapeutics to develop novel T-cell-based therapies in a deal that includes an option to buy the year-old UK biotech.

As the name suggests, GammaDelta is focused on using gamma delta T-cells to treat disease. Unlike alpha beta and B cells that bind specific foreign receptors, alpha delta cells respond to a range of chemical signals released by stressed cells.

The idea is that gamma delta-based cell therapies will be able to recognize a wider variety of tumours. In addition, because gamma delta cells do not target specific receptors, cancerous cells cannot evade detection by modifying expression patterns.

GammaDelta did not respond to a request for additional information. On its website the firm claims it is able to isolate gamma delta cells, culture them and turn into therapies.

$100m R&D deal

Takeda – and GammaDelta’s venture capital backer Abingworth LLC – have committed $100m (€92m) to the partnership, some of which will be used to fund R&D.

Daniel Curran, head of Takeda’s Center for External Innovation, said: “This collaboration is another example of our strategy to invest in highly innovative areas of science and we’re pleased to collaborate with the experienced team at GammaDelta​.”

The deal – which gives Takeda an equity stake in GammaDelta as well as the option to buy – is similar to the $125m agreement it struck with T cell developer Maverick Therapeutics Inc. in January.

The option to acquire is in keeping with its $35m agreement with PvP Biologics, also signed in January.

Related news

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers

Follow us

Webinars